Keros Therapeutics director Bienaime buys $10,270 in shares
Keros Therapeutics director Bienaime recently increased his stake in the company by purchasing 1,000 shares on August 17, 2026. The director spent $10,270 on the transaction, which was executed in line with a pre-existing Rule 10b5-1 trading plan adopted in December 2025. After completing the purchase, Bienaime now owns a total of 19,592 shares of Keros Therapeutics common stock.
With KROS shares trading close to their 52-week low of $9.69, down 45% year-to-date to $11.23, the insider's move may be considered timely. The company's financial position remains robust, with a strong current ratio of 21.96 and more cash than debt on its balance sheet; however, the company is rapidly consuming its cash reserves.
Keros Therapeutics has also recently appointed Anne Prener, M.D., Ph.D., as a new board member, contributing her expertise in pharmaceuticals and innovation to the leadership team.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
